Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatment

Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatment

US Patent 12144839 · Granted Nov 19, 2024

Estimated economic value: $425,732,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bacterial and cell compositions for the treatment of colorectal cancer and metho2025
Immune checkpoint inhibitor combinations2025
Immunogenic sequences from a phage tail length tape measure protein, bacteria ex2024
Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 an2023
Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 an2023
Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 an2023
Microbiota composition, as a marker of responsiveness to chemotherapy, and use o2022
Immune checkpoint inhibitor combinations2021
Combination of oncolytic virus with immune checkpoint modulators2020
Microbiota composition, as a marker of responsiveness to chemotherapy, and use o2020
Methods for predicting the sensitivity of a subject to immunotherapy2017
Natural killer p30 (NKp30) dysfunction and the biological applications thereof2017